Quantcast

Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA

June 24, 2009

AMSTERDAM, The Netherlands, June 24 /PRNewswire/ — The U.S. Department
of Energy’s Pacific Northwest National Laboratory has signed an agreement
with Avantium to enable the sale and delivery of an Avantium Flowrence(TM)
parallel fixed bed reactor system. The Flowrence(TM) will allow PNNL to
accelerate its catalyst research for infrastructure compatible biofuels and
bioproducts.

PNNL is operated by Battelle for the U.S. Department of Energy. The
Laboratory advances science and develops solutions for global challenges at
the energy and environment nexus. PNNL scientists have extensive expertise in
catalysis and reaction engineering, with particular focus on solutions for
efficient use of bioproducts, converting biomass and renewable feedstocks to
fuels and chemicals, and reducing environmental emissions.

The Avantium system will be housed in the Bioproducts, Sciences and
Engineering Laboratory (BSEL). BSEL is a multipurpose research and
development facility that includes operating space for all activities
required to advance the science and engineering of processes for bio-based
product manufacture. The building is located on the campus of Washington
State University Tri-Cities Campus
in Richland, Washington, approximately one
mile south of the main campus of PNNL.

Tom van Aken, Chief Executive Officer of Avantium: “The sale of
Flowrence(TM) platforms to a world leading research center such as PNNL is a
recognition of the value of Avantium’s proprietary high-throughput R&D
technology. We are proud to provide our unique Flowrence technology to PNNL
to help increase PNNL’s R&D productivity significantly with our methodology.”

Avantium’s proprietary parallel fixed bed rector technology has been
successfully applied for over 9 years in collaboration programs for gas,
liquid and trickle flow applications (e.g. hydrotreating, VGO hydrocracking,
selective oxidation and selective hydrogenation). The Flowrence(TM) is
Avantium’s proprietary commercially available parallel fixed bed reactor
system. The system consists of 16 reactors (4 blocks of 4 reactors each)
tailored to the clients applications enabling them to enhance their catalysis
research and process optimization efforts. Flowrence(TM) enables users to
test catalytic materials for a range of chemistries under industrial
processing conditions, including high-temperature (up to 850 0C) and
high-pressure reactions (up to 180 Bar).

Profile Avantium

Avantium is a leading technology company specialized in the area of
advanced high-throughput R&D. The company develops and commercializes
Furanics, a next generation biofuels and bioplastics, and develops improved
forms of existing drugs. Avantium has demonstrated the value and commercial
potential of its unique technology and knowledge by collaborating with
leading companies in the energy, chemical and pharmaceutical industry.
Avantium’s customer base for its R&D services and systems offering consists
of more than 70 companies worldwide, including market leaders such as BP,
Shell, Sasol, Pfizer and GSK. Avantium has around 140 employees; its offices
and headquarters are based in Amsterdam, the Netherlands.

Flowrence(TM)

For more information about Flowrence(TM), including downloads and
pictures, please visit http://www.avantium.com/flowrence. Flowrence(TM) is a
trademark of Avantium.

http://www.avantium.com

SOURCE Avantium Technologies B.V.


Source: newswire



comments powered by Disqus